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1013-7025/Copyrightª 2015, Hong Kong PhAbstract Background: The prevalence of nonspecific low back pain is very high among Niger-
ians and in Africa. Lofnac Gel is a nonsteroidal anti-inflammatory gel that has been used to
treat musculoskeletal pain, but its efficacy on nonspecific low back pain is inconclusive.
Objective: The objective of this study was to examine the therapeutic efficacy of Lofnac Gel in
the management of nonspecific low back pain.
Methods: Seventy patients diagnosed with mechanical low back pain of 3 months’ duration
were divided into two groups: experimental group (n Z 35) and control group (n Z 35). Par-
ticipants in both groups were placed on supervised strengthening exercises for multifidus mus-
cles of the low back. The experimental group was placed on ultrasound phonophoresis therapy
with Lofnac Gel (with diclofenac and methyl salicylate as active ingredients), whereas the con-
trol group was placed on ultrasound with water as coupling medium. The treatment was
applied twice per week for 6 weeks. Present pain intensity and disability were measured
before treatment, and in the 3rd week and 6th week of treatment. Data were analysed using
descriptive and inferential statistics, and post hoc analysis was carried out when necessary.
Results: There was a significant difference between the pre- and posttreatment pain intensity
and disability index for both the experimental (FZ 17.947, p < 0.001; FZ 20.712, p < 0.001)
and control (FZ 14.791, p < 0.001; FZ 10.418, p < 0.001) groups. There was also a significant
difference between the experimental and control group data in terms of pain intensity
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90 A.O. Ojoawo et al.Conclusion: Exercise combined with Lofnac phonophoresis was more effective in the manage-
ment of patients with chronic low back pain than exercise and ultrasound alone.
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Low back pain (LBP) is a major cause of morbidity in high,
middle, and low-income countries, and it affects 80e85% of
people over their lifetime [1]. In Africa, Louw et al [2] re-
ported that the mean LBP prevalence rate was 12% among
adolescents and 32% among adults [2]. Omokhodion [3] also
conducted a survey in the south-western part of Nigeria and
found that 40% of the sample population had LBP in the past
12 months, whereas 33% had LBP at the time of study,
indicating that LBP is a common condition among Africans
that is rising and should be of concern [3].
Specific LBP occurs in approximately 2% of all patients
with back complaints [4]. For the majority of patients with
LBP, a specific diagnosis cannot be defined on the basis of
anatomical or physiological abnormalities, but nonspecific
low back pain (NSLBP) is assumed to be inflammatory or
mechanical in nature [5]. Chronic NSLBP refers to an
episode of activity-limiting LBP (with no pain referred into
either lower limb) that lasts for  3 months [6]. Mechanical
LBP is the general term that refers to any type of back pain
caused by strain on muscles of the vertebral column and
abnormal stress [7]. The main objective of treatment for
chronic LBP is for the patient to return to their desired level
of activities and participation, as well as the prevention of
chronic complaints and recurrences [8]. Several different
treatments are used including anti-inflammatory agents.
Diclofenac and methyl salicylate are nonsteroidal anti-
inflammatory topical drugs (NSAIDs) used to treat lower
extremity (i.e., knees, ankles, feet) joint pain [9]. Topical
administration of NSAIDs can allow for an efficient, painless
delivery of medication that may reduce systematic side
effects associated with medication while providing clinical
advantage over injected or oral administration for the same
clinical situation [10]. In addition, topical medication can
target the painful and inflamed site and ideally produce
effective drug concentration locally with minimal systemic
absorption [10]. Ultrasound application can assist by pro-
moting the transport of the compound through the skin, a
method sometimes called sonophoresis or phonophoresis
(as opposed to electrophoresis) [11]. The addition of active
agents (e.g., anti-inflammatory drugs) to the gel is widely
practised, but remains scarcely researched. The level of
clinical benefit to the patient from physical therapy ultra-
sound treatments with Lofnac Gel (manufactured by
Gopaldas Visram Co. Ltd, Mumbai, India; marketed by
Green life Pharmaceutical, Lagos, Nigeria) remains uncer-
tain, and there is little evidence that continuous thera-
peutic ultrasound with Lofnac Gel is more effective than
ultrasound with coupling medium only for treating people
with NSLBP. More importantly, diclofenac and methyl sa-
licylate are commonly used separately as topical gel in
physiotherapy for pain relief especially on kneeosteoarthritis [12,13]. The efficacy of using these drugs
together using phonophoresis on chronic NSLBP is not well
documented. The study is designed to examine the efficacy
of ultrasound phonophoresis using Lofnac Gel on pain and
disability in patients with chronic NSLBP.
Materials and methods
Study design
This study was a single blinded randomised controlled trial
comparing two active interventions.
Participants
Inclusion and exclusion criteria
Patients with NSLBP with pain lasting for >3 months were
sought for the study. Patients with nerve root symptoms,
underlying systemic or visceral disease, and specific con-
ditions such as neoplasm, fractures, ankylosing spondylitis,
previous low back surgery, and pregnancy were excluded.
Patients taking any medications for specific psychological
problems were also excluded.
Recruitment procedures
Patients with chronic NSLBP referred for treatment were
recruited from the Department of Medical Rehabilitation,
Obafemi Awolowo University Teaching Hospital Complex Ife
Hospital Unit, Ile Ife, Nigeria. Patients were screened to
determine whether they fulfilled the eligibility criteria.
Those who were considered eligible were provided with oral
andwritten information about the study. After consent forms
were signed and obtained, the patientswere randomised into
two groups.
Sample size determination
For a study comparing two means, the equation for sample
size described by Rosner [14] was used:
N
4s2

Zcrit þ Zpwr
2
D2
;
where N is the total sample size (the sum of the sizes of
both comparison groups); s is the standard deviation
assumed to be equal for both groups; Zcrit is assumed to be
1.960; Zpwr Z 0.842; and D is the minimum expected dif-
ferences between the two means, which amounted to 35
for each group. Thirty-five patients were randomised for
the experimental group, and another 35 were assigned to
the control group.
Ethical approval was obtained from the Institute of
Public Health Obafemi Awolowo University Ile-Ife, and
informed consent of the participants was obtained. All
91procedures followed the principles described in the Decla-
ration of Helsinki.
Instrumentation
The instruments used in this study consisted of a height
meter, a Hanson bathroom scale (Gravitation Ltd., Kilmes-
san, County Meath, Ireland), the verbal rating scale (VRS),
the RolandeMorris Back Pain and Disability Questionnaire
(RMDQ), and an ultrasound machine (continuous mode;
Sonopuls 490, Enraf-Nonius B.V., Rotterdam, The
Netherlands).
The active ingredients of Lofnac Gel (Bliss GOS Pharma
Ltd., Marashtra, India) are diclofenac diethylamine (1.16%)
and methyl salicylate (10.00%).
Interventions
Patients in each group received 12 sessions of treatment,
within a period of 6 weeks. Group A (experimental group)
received Lofnac Gel through phonophoresis with exercise,
whereas Group B (control group) received ultrasound with
coupling medium and exercise.
Ultrasound application
In this study, the ultrasound machine was tested according
to Kitchen and Bazin [15]. The treatment head was
immersed in water, after which the machine was turned on
and adjusted to a continuous mode. The output of the
machine was observed from the bubbling of the water
molecules. The patients in both groups received continuous
ultrasound using Sonopuls 490s operated at a frequency of
1 MHz and intensity of 1.5 W/cm2 (spatial average temporal
average) according to Ebadi et al [16], Ansari et al [17], and
Durmuz et al [18]. Slow circular movement was applied by
the transducer head over the paravertebral low back region
for 10 minutes. For the experimental group, 10 mL Lofnac
Gel was applied on the painful area of Lumbar 3, 4, 5, and
S1 within a circle having a radius of 6 cm. Slow circular
movement was applied by the transducer head over the
multifidus muscles of the low back and the spinal process
within this radius.
The supervised exercise routine prescribed to patients
was as follows: extension of the thoracolumbar spine from
prone lying, trunk bending backwards with arms turning
outward; trunk bending backwards with arm turning out-
wards and single leg raising backwards according to Colson
and Collison [19]. Patients were asked to perform the ex-
ercises for 10 repetitions each for 10 times during each
treatment session, depending on the ability of each pa-
tient. After completion of treatment sessions, patients
were advised to continue staying active and to visit the
clinic twice per week for their treatment, which continued
for 6 weeks.
Avoiding cointervention
Patients were told not to commence new pain medications
during the intervention period (from the beginning of
treatment sessions until the end of the 6-week treatmentperiod) and to refrain from participating in any other ex-
ercise or treatment programme.
Outcome measures
Each patient’s details such as age, sex, body mass index,
and present pain intensity were recorded at the baseline
assessment. All primary and secondary outcome measures
were measured by a coauthor before treatment and also
after each week of treatment. Data for pretreatment, 3rd
week of treatment, and 6th week of treatment were used
for the data analysis.
Primary outcome was measured with the VRS. The VRS
was validated with the visual analogue scale by Williamson
and Hoggart [20], who concluded that VRS provides a useful
alternative to the visual analogue scale scores in the
assessment of chronic pain. VRS was used to measure pre-
sent paindi.e., pain at the time of study.
The secondary outcome measure was RMDQ. RMDQ is a
commonly utilised instrument for measuring spinal
disability as an outcome measure [21]. This 24-item ques-
tionnaire was derived from the Sickness Index Profile by
Bergner et al [22]. RMDQ is easy to score; it entails totalling
the sum of circled items (maximum is 24), thus representing
the final score. According to Von Korff and Saunders [23], a
RMDQ cutoff score of 14 represents significant disability
associated with an unfavourable outcome [23]. The
RolandeMorris study [21] is referred to as the best single
study to assess the short-term outcome of primary care
patients with LBP.
Data analysis
The data were analysed using SPSS 16 (SPSS Inc., Chicago,
IL, USA). Descriptive statistical and inferential statistics
was used to analyse the data. Repeated-measures analysis
of variance was used to compare the mean values of pre-
treatment, 3rd week, and 6th week data within the control
group and also the experimental group. Post hoc analysis
using Tukey’s honestly significant difference was conducted
when necessary.
Results
Fig. 1 illustrates the flow of participants through the study.
Overall, 126 patients with LBP were examined: 15 had acute
LBP, 20 had identifiable pathology, and 21 refused to
participate in the study; 70 (55.5%) participated in the study.
The 70 patients were randomly assigned to one of the
two groups; ultrasound with Lofnac Gel phonophoresis or
ultrasound only. Seventy ballot papers were prepared with
inscriptions of L.P on 35 and U.O on another 35. Patients
were asked to pick one of the papers as soon as they were
deemed suitable for the study. Those who picked L.P were
assigned to the Lofnac phonophoresis group and the others
formed the Ultrasound only group.
The following details were recorded in each group: mean
age, weight, height, body mass index, waist circumference,
hip circumference, waist hip ratio, and male/female ratio.
The results showed that there was no significant difference
between the anthropometric parameters of the two groups
Figure 1. Flowchart for the randomised controlled trial.
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considered to be comparable in all physical characteristics.
Thus, any difference found in this study could be attributed
to “treatment effect” rather than variations in the groups’
physical characteristics.Table 1 Physical characteristics of the participants.
Variables Experimental
(n Z 35)
Control
(n Z 35)
T p
Mean  SD Mean  SD
Age (y) 46.3  10.1 49.3  9.7 0.012 0.921
Weight (kg) 74.4  12.6 69.5  12.2 0.233 0.632
Height (m) 1.64  0.12 1.62  0.08 2.042 0.161
BMI (kg/m2) 27.6  3.6 26.6  4.5 0.403 0.402
Wst C (cm) 86.8  13.9 91.0  13.8 0.034 0.874
Hip C (cm) 93.5  9.8 99.0  12.6 0.291 0.591
WHR 0.92  0.06 0.92  0.03 2.292 0.140
KOA/y 1 1.2 0.652 0.542
M:F 4:11 1:14
BMI Z body mass index, F Z female; Hip C Z hip circumfer-
ence; KOA/y Z duration of knee osteoarthritis per year;
M Z male; SD Z standard deviation; WHR Z waist/hip ratio;
Wst C Z waist circumference.Table 2 is the comparison within pretreatment, 3rd
week, and 6th week pain intensity and disability index of
the experimental and control groups. There was a signifi-
cant difference between pretreatment, 3rd week, and 6th
week pain intensity for the experimental (F Z 17.947,
p < 0.001) and control (F Z 20.712, p < 0.001) groups.
There was also a significant difference between pretreat-
ment, 3rd week, and 6th week disability index of the
experimental (F Z 14.791, p < 0.001) and control
(F Z 10.418, p < 0.001) groups. The difference in the
experimental group pain intensity between baseline and
the 3rd week is 3.0, whereas that between the 3rd week and
6th week is 1.3; meanwhile, that of the control group is 2.2
between baseline and the 3rd week and 1.1 between the 3rd
week and 6th week. Moreover, the difference in disability
index for the experimental group was 4.5 and 3.4 between
baseline and the 3rd week for the experimental group and
the control group, respectively.
Table 3 compares the pretreatment, 3rd week, and 6th
week pain intensity values across the two groups. There
was no significant difference between the pretreatment
pain intensity value of both experimental and control
groups at baseline. There was significant difference in the
3rd week and 6th week pain intensity value (F Z 28.763,
p < 0.001) across the two groups. There was also a
Table 2 Comparison of pre- and posttreatment pain intensity and disability index within the experimental group and control
group.
Experimental group (n Z 35) Control group (n Z 35)
Baseline 3rd wk 6th wk Baseline 3rd wk 6th wk
Pain intensity Mean  SD 5.9  1.6 2.9  1.0 1.6  0.6 5.7  1.7 3.5  1.4 2.5  1.1
F 17.947 20.712
p <0.001* <0.001*
Disability index Mean  SD 9.9  2.2 5.3  2.6 2.5  1.7 9.4  2.1 6.0  3.1 5.1  2.9
F 14.791 10.418
p <0.001* <0.001*
*Significant at p < 0.001.
F Z calculated F, which determines the significance; SD Z standard deviation.
93significant difference in the 3rd week and 6th week disability
index (F Z 39.817, p < 0.001) across the two groups.
Discussion
The purpose of this study was to determine the therapeutic
efficacy of Lofnac phonophoresis with exercise, and exer-
cise with ultrasound and ultrasonic gel on pain and disability
of patients with chronic NSLBP. The present study demon-
strated significantly more improvements in pain intensity
and disability index in the experimental group than the
control group. The results thus indicated that supervised
exercise with Lofnac phonophoresis is more effective than
exercise and ultrasound alone in reducing pain and disability
in patients with chronic NSLBP. There is also an indication
that patients responded more positively to the treatment
within the first 3 weeks than in the subsequent weeks. The
effect of exercise as observed in the two groups supported
the work of Linton and Van Tulder [24], who concluded that
only exercises provided sufficient evidence that it is an
effective intervention in ameliorating low back pain.
There was a significant decrease in pain intensity and
disability index between the experimental group and theTable 3 Comparison of pre- and posttreatment pain in-
tensity and disability index across the two groups.
Experimental
(n Z 35)
Control
(n Z 35)
F p
Mean  SD Mean  SD
Pain intensity
Pretreatment 5.9  1.6a 5.7  1.7a
3rd wk 2.9  1.0b 3.5  1.4d 28.763 <0.001*
6th wk 1.6  0.6c 2.5  1.1e
Disability index
Pretreatment 9.9  2.2a 9.4  2.1a
3rd wk 5.3  2.6b 6.0  3.1d 39.817 <0.001*
6th wk 2.5  1.7c 5.1  2.9e
Post hoc Tukey’s honestly significant difference. Superscript
lettersdmean mode with the same superscripts indicates no
significant difference between mean; mean mode with
different superscripts indicates significant difference.
The 10-point verbal rating scale was used.
*Significant at p < 0.001.
SD Z standard deviation.control group from the 3rd week. This may be associated
with the additional analgesic and anti-inflammatory effect
of Lofnac Gel to the effect of exercise. Lofnac Gel contains
diclofenac and methyl salicylate as active ingredients, both
of which are NSAIDs and analgesics that work by inhibiting
the effect of cyclooxygenase enzymes. Cyclooxygenase en-
zymes help to produce prostaglandins, which are produced
at the site of the injury or damage tissues that cause pain
and inflammation [25]. Over the past two decades, evidence
has emerged to demonstrate that topical versions of NSAIDs
are well absorbed through the skin and reach therapeutic
levels in synovial fluid, muscle, and fascia [26]. Nonspecific
back pain may originate from many spinal structures,
including ligaments, facet joints, the paravertebral muscu-
lature and fascia, the intervertebral disc, and inflammation
of dorsal root ganglion (DRG) [27]. Thus, the combination of
lofnac phonophoresis with exercise seems to produce
greater pain and disability reduction. The effect of diclo-
fenac and methyl salicylate in LBP is similar to that
described in the report of Huang et al [28], which provided
evidence that anti-inflammatory reagents can reduce pain
due to intervertebral foramen inflammation in a rat model.
Anti-inflammatory cream inhibited hyperexcitability of the
inflamed DRG neurons and upregulation of Nav1.7 and
Nav1.8 protein, respectively. It also markedly improved the
pathological manifestations of the inflamed DRG. Further-
more, in inflamed DRGs, phosphorylation and expression of
transcription factor NF-kB and proinflammatory enzyme
cyclooxygenase-2 were significantly increased, whereas the
cytokine interleukin-1b level was increased.
Limitations
The main limitation of this study could be that the physio-
therapist who treated the patients was not blinded to the
group allocation, and the assessors were not totally inde-
pendent of the intervention. This is because the clinic
administrationdoesnotpermitblinding.Thestudyalsodidnot
have a third group that focused on exercise alone; therefore,
the effect of ultrasound only cannot be determined.Conclusion
It could be concluded from the study that the reduction in
pain intensity and disability index in the exercise with
94 A.O. Ojoawo et al.Lofnac phonophoresis group was greater than that in the
control group from the 3rd week of intervention. This study
showed that Lofnac phonophoresis with exercise can be
used to help ameliorate pain and disability of patients with
NSLBP.
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